Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of “Buy” from Brokerages

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned a consensus recommendation of “Buy” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year is $31.14.

Several analysts recently commented on CPRX shares. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, November 8th. Truist Financial lifted their price objective on shares of Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Finally, Stephens began coverage on shares of Catalyst Pharmaceuticals in a research note on Monday, November 18th. They set an “overweight” rating and a $35.00 target price for the company.

Catalyst Pharmaceuticals Trading Up 0.2 %

Shares of NASDAQ CPRX opened at $21.38 on Friday. The stock has a market cap of $2.55 billion, a P/E ratio of 18.12, a P/E/G ratio of 3.35 and a beta of 0.75. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.27. The stock has a 50 day moving average of $21.62 and a two-hundred day moving average of $19.14.

Insider Buying and Selling

In related news, Director Molly Harper sold 17,500 shares of the company’s stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total transaction of $385,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the sale, the insider now directly owns 686,996 shares of the company’s stock, valued at approximately $15,065,822.28. This trade represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock valued at $1,754,140 over the last ninety days. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. boosted its holdings in Catalyst Pharmaceuticals by 3.4% during the third quarter. Franklin Resources Inc. now owns 59,164 shares of the biopharmaceutical company’s stock worth $1,221,000 after buying an additional 1,967 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $667,000. Hohimer Wealth Management LLC purchased a new stake in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $329,000. Vestcor Inc grew its holdings in shares of Catalyst Pharmaceuticals by 18.4% in the 3rd quarter. Vestcor Inc now owns 60,431 shares of the biopharmaceutical company’s stock worth $1,201,000 after acquiring an additional 9,379 shares during the period. Finally, Barclays PLC increased its stake in Catalyst Pharmaceuticals by 129.4% in the 3rd quarter. Barclays PLC now owns 248,458 shares of the biopharmaceutical company’s stock valued at $4,939,000 after purchasing an additional 140,129 shares in the last quarter. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.